Skip to main content
Log in

The Biphenyl-Carboxylate Derivative ABD328 is a Novel Orally Active Antiresorptive Agent

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

We previously described a novel series of biphenyl carboxylic acid derivatives which have potent antiresorptive effects in vitro and in vivo and do not affect osteoblast function. However, none of the previous compounds showed oral activity, probably because they were esters, which would be expected to be metabolized very rapidly. Here, we tested whether derivatives where the ester link was replaced by a ketone link were orally active. Compounds were tested in murine osteoclast and osteoblast cultures and in the mouse ovariectomy (OVX) model of osteoporosis. The ketones were at least as potent at inhibiting osteoclast formation and RANKL signaling in vitro as the esters and did not inhibit osteoblast differentiation or function. The basic ketone-linked compound ABD68 was only partially able to inhibit OVX-induced bone loss at an oral dose of 20 mg/kg daily. Substitutions on the phenyl rings increased the potency of the compounds in vitro and may prevent metabolism of the compounds in vivo. The most promising derivative, ABD328, completely prevented OVX-induced bone loss when administered by intraperitoneal injection at 3 mg/kg daily. Furthermore, ABD328 was also able to fully prevent OVX-induced bone loss when given orally at 10 mg/kg daily. The results indicate that biphenyl carboxylates like ABD328 are oral candidate drugs for the treatment of diseases characterized by increased bone resorption, such as postmenopausal osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. van’t Hof RJ, Idris AI, Ridge SA, Dunford J, Greig IR, Ralston SH (2004) Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors. J Bone Miner Res 19:1651–1660

    Article  Google Scholar 

  2. Idris AI, Greig IR, Bassonga-Landao E, Ralston SH, van’t Hof RJ (2009) Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation. Endocrinology 150:5–13

    Article  CAS  PubMed  Google Scholar 

  3. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508–1514

    Article  CAS  PubMed  Google Scholar 

  4. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215

    Article  CAS  PubMed  Google Scholar 

  5. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226

    Article  CAS  PubMed  Google Scholar 

  6. Idris A, Mrak E, Greig I, Guidobono F, Ralston SH, van’t Hof R (2008) ABD56 causes osteoclast apoptosis by inhibiting the NFkappaB and ERK pathways. Biochem Biophys Res Commun 371:94–98

    Article  CAS  PubMed  Google Scholar 

  7. van’t Hof RJ, Macphee J, Libouban H, Helfrich MH, Ralston SH (2004) Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology 145:5068–5074

    Article  PubMed  Google Scholar 

  8. van’t Hof RJ (2003) Osteoclast formation in the mouse coculture assay. In: Helfrich MH, Ralston SH (eds) Bone research protocols. Humana Press, Totowa, NJ, pp 145–152

    Chapter  Google Scholar 

  9. Stewart TL, Roschger P, Misof BM, Mann V, Fratzl P, Klaushofer K, Aspden RM, Ralston SH (2005) Association of COLIA1 Sp1 alleles with defective bone nodule formation in vitro and abnormal bone mineralisation in vivo. Calcif Tissue Int 77:113–118

    Article  CAS  PubMed  Google Scholar 

  10. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603–610

    Article  CAS  PubMed  Google Scholar 

  11. Gasser JA, Kneissel M, Thomsen JS, Mosekilde L (2000) PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 1:53–56

    CAS  PubMed  Google Scholar 

  12. Samadfam R, Xia Q, Goltzman D (2007) Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55–63

    Article  CAS  PubMed  Google Scholar 

  13. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751

    Article  CAS  PubMed  Google Scholar 

  14. Idris AI, Rojas J, Greig IR, van’t Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191–201

    Article  CAS  PubMed  Google Scholar 

  15. Orriss IR, Key ML, Colston KW, Arnett TR (2009) Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106:109–118

    Article  CAS  PubMed  Google Scholar 

  16. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75–85

    Article  CAS  PubMed  Google Scholar 

  17. Yamane H, Sakaia A, Moria T, Tanakaa S, Morideraa K, Nakamura T (2009) The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 44:1055–1062

    Article  CAS  PubMed  Google Scholar 

  18. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182–195

    Article  CAS  PubMed  Google Scholar 

  19. Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL (2010) Are osteoclasts needed for the bone anabolic response to PTH? A study of intermittent PTH With denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 285:28164–28173

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by grants from the Arthritis Research Campaign UK and Scottish Enterprise and by an ECTS/Amgen fellowship award to A. I. I.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Aymen I. Idris or Rob J. van’t Hof.

Additional information

Idris, Greig, Ralston and van’t Hof are inventors on UK patent WO2004/098582 Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions, held by the University of Aberdeen. Coste has stated no conflict of interest

Rights and permissions

Reprints and permissions

About this article

Cite this article

Idris, A.I., Coste, E., Greig, I.R. et al. The Biphenyl-Carboxylate Derivative ABD328 is a Novel Orally Active Antiresorptive Agent. Calcif Tissue Int 87, 525–532 (2010). https://doi.org/10.1007/s00223-010-9417-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-010-9417-5

Keywords

Navigation